DND – A New Device for Diabetic Neuropathy Testing Guest: Daniel Medrano, CEO of Medrano & Associates LLC Viv Hudson and Michael Berg of Ancillary Medical Solutions speak with Daniel Medrano, CEO of Medrano & Associates LLC, about the DND, a hand-held diabetic neuropathy device for in-office evaluation. This issue (10:42): – What is the […]
Ancillary Trends
-
-
Posted in:
In-Office Visco-Supplementation Treatment Program for Osteoarthritis [90]
Peter Polack Comments are off
In-Office Visco-Supplementation Treatment Program for Osteoarthritis In-Office Visco-Supplementation Treatment Program for Osteoarthritis Guest: Dr Josh Brown, Internal Medicine Specialists Viv Hudson and Michael Berg of Ancillary Medical Solutions speak with guest Dr Josh Brown about a new and complete program for physicians to treat patients in-office with osteoarthritis using visco-supplementation. This issue (12:32) which patients […]
-
A New Device for Testing Diabetic Neuropathy Guest: Dr Boris Golosarsky of Prosenex Viv Hudson and Michael Berg of Ancillary Medical Solutions speak with Dr Boris Golosarsky, the inventor of a novel device for in-office testing for diabetic neuropathy. This issue (17:45): Introducing a new device for more effectively measuring patients’ nerve health How to […]
-
Ancillary Services to Help Physicians Meet MACRA Guest: Michael Berg and Viv Hudson of Ancillary Medical Solutions Michael Berg, CEO of Ancillary Medical Solutions and Vivien Hudson, pharmacist and Marketing Manager at Ancillary Medical Solutions discuss a variety of ancillary services that can help physicians boost their composite scores for MACRA and MIPS. This issue […]
-
In-Office Neuroscience Testing Guest: John Armstrong, Evoke Neuroscience Viv Hudson and Michael Berg of Ancillary Medical Solutions speak with John Armstrong of Evoke Neuroscience regarding in-office neuroscience testing of cognitive disorders in the primary care setting. This issue (12:36): How using brain mapping biomarkers can be used in the primary care setting How to determine […]
